Scott Cameron, M.D., Ph.D., was appointed Head, Radioligand Therapy (RLT) Early Clinical Development for Advanced Accelerator Applications, a Novartis company, in September 2020. Prior to joining AAA, Scott served as Executive Clinical Program Leader, Oncology, Translational Clinical Oncology (TCO) with the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, since 2017. From 2010 to 2017, Scott served as Director, and later as Senior Director and Clinical Program Leader, TCO, at NIBR where he was responsible for the design, conduct and results reporting of clinical studies investigating new cancer therapies. He directed multiple programs within TCO and led the immune-oncology working group, developing a deep understanding of translational oncology. Prior to joining Novartis, Scott was Director of Research at Children’s Medical Center in Dallas, Texas and also served as Co-Chair, Development and Cancer Scientific Program at the Simmons Cancer Center in Dallas from 2006 to 2010. Earlier in his career, Scott spent 12 years at Harvard/Massachusetts Institute of Technology (MIT), where he trained to become a pediatric hematologist/oncologist. He then joined the faculty at University of Texas Southwestern Medical Center in Dallas, where he led the genetics program and cared for pediatric cancer patients. Other academic appointments included Instructor in Pediatrics at Harvard Medical School, as well as Attending Physician at Children’s Hospital and the Dana-Faber Cancer Institute, both in Boston, Massachusetts. Scott holds a medical doctorate from Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology. He also completed his Ph.D. in Genetics at Cold Spring Harbor Laboratories, State University of New York, Stony Brook, and earned a B.A. in Chemistry at The Johns Hopkins University in Baltimore, Maryland.